Clinical Trial Update: Trial to Assess the Pharmacokinetics, Safety, Tolerability of Oral Brexpiprazole in Children (6 to <13 Years Old) With Central Nervous System Disorders [Phase 1]

View source ↗

Summary

Phase 1 trial update evaluating pharmacokinetics, safety, and tolerability of oral brexpiprazole in children 6 to <13 with CNS disorders; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder
• Autism Spectrum Disorder
• Bipolar Disorder
• Conduct Disorder
• Oppositional Defiant Disorder

Drugs mentioned

• REXULTI (brexpiprazole)

Snippet

Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. | Conditions: ADHD, Autism | Phase 1 | Status: COMPLETED